Ascletis Pharma Inc. (Ascletis-B) has filed its Monthly Return for Equity Issuer covering the period to 31 October 2026, revealing a stable capital structure and confirmation of full public-float compliance.

Authorised Capital • The company’s authorised share capital remained unchanged at 7.00 billion ordinary shares with a par value of USD 0.0001 each, representing total authorised capital of USD 0.70 million.

Issued and Treasury Shares • Issued shares (excluding treasury shares) closed the month at 1.05 billion, while treasury shares stood at 5.78 million, leaving the total issued share count at 1.06 billion. • No new shares were issued and no treasury shares were cancelled or transferred during October. • Ascletis confirmed that it continued to satisfy the Hong Kong Stock Exchange’s minimum 25% public-float requirement.

Share Option Activity • 2019 Share Option Scheme: Outstanding options fell by 0.15 million to 5.89 million after cancellations. Remaining options that could be exercised or settled in shares total 3.06 million. • 2025 Share Option Scheme: Outstanding options remained at 5.45 million, with 1.33 million shares available for potential exercise and a further 33.09 million shares reserved for future grants. • No options were exercised in October; consequently, the company raised no proceeds from option exercises.

Share Repurchases Pending Cancellation • Ascletis repurchased a cumulative 5.50 million ordinary shares between 30 June and 30 October 2026 for cancellation. These shares had not been cancelled as of 31 October 2026.

Other Capital Instruments • The issuer reported no outstanding warrants, convertible securities, or other share-issuance agreements during the month.

Overall, Ascletis-B entered November 2026 with an unchanged share base, maintained regulatory public-float thresholds, and showed limited equity dilution risk, while carrying a modest volume of repurchased shares pending formal cancellation.